Loss of the BCR-FGFR1 GEF Domain Suppresses RHOA Activation and Enhances B-Lymphomagenesis in Mice.
暂无分享,去创建一个
J. Cowell | H. Qin | N. Savage | M. Ren | Sumin Lu | Tianxiang Hu | Yating Chong | Chang-Sheng Chang
[1] E. Kitamura,et al. The miR-17/92 cluster is involved in the molecular etiology of the SCLL syndrome driven by the BCR-FGFR1 chimeric kinase , 2017, Oncogene.
[2] L. Medeiros,et al. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase. , 2017, Human pathology.
[3] A. Pandey,et al. Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis , 2017, Leukemia.
[4] O. Hantschel,et al. Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics , 2017, Leukemia.
[5] E. Kitamura,et al. A model of BCR‐FGFR1 driven human AML in immunocompromised mice , 2016, British journal of haematology.
[6] Edd Ricker,et al. Faculty of 1000 evaluation for Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. , 2016 .
[7] S. Malek,et al. Targeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models , 2016, Oncotarget.
[8] J. Zehnder,et al. Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia , 2016, Leukemia.
[9] O. Nureki,et al. Variegated RHOA mutations in adult T-cell leukemia/lymphoma. , 2016, Blood.
[10] N. Itoh,et al. The Fibroblast Growth Factor signaling pathway , 2015, Wiley interdisciplinary reviews. Developmental biology.
[11] M. Olson,et al. Rho-associated coiled-coil containing kinases (ROCK) , 2014, Small GTPases.
[12] Min Kyung Sung,et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma , 2014, Nature Genetics.
[13] O. Nureki,et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma , 2014, Nature Genetics.
[14] I. Lossos,et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas , 2014, Nature Genetics.
[15] S. Narumiya,et al. Physiological roles of Rho and Rho effectors in mammals. , 2013, European journal of cell biology.
[16] K. Green,et al. The GEF Bcr activates RhoA/MAL signaling to promote keratinocyte differentiation via desmoglein-1 , 2013, The Journal of cell biology.
[17] David A. Williams,et al. Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression , 2012, Leukemia.
[18] J. Cowell,et al. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities , 2012, Leukemia.
[19] J. Cowell,et al. Acute Progression of BCR-FGFR1 Induced Murine B-Lympho/Myeloproliferative Disorder Suggests Involvement of Lineages at the Pro-B Cell Stage , 2012, PloS one.
[20] J. Cowell,et al. Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease. , 2011, Blood.
[21] K. Kaibuchi,et al. Rho-Kinase/ROCK: A Key Regulator of the Cytoskeleton and Cell Polarity , 2010, Cytoskeleton.
[22] L. Medeiros,et al. 8p11 myeloproliferative syndrome: a review. , 2010, Human pathology.
[23] N. Turner,et al. Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.
[24] Xiurong Li,et al. Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. , 2009, Blood.
[25] P. L. Rodriguez,et al. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation , 2008, Oncogene.
[26] David A. Williams,et al. Inhibition of RhoA GTPase activity enhances hematopoietic stem and progenitor cell proliferation and engraftment. , 2006, Blood.
[27] Alan Hall,et al. Rho GTPases: biochemistry and biology. , 2005, Annual review of cell and developmental biology.
[28] Andrei V Bakin,et al. WAVE3 promotes cell motility and invasion through the regulation of MMP-1, MMP-3, and MMP-9 expression. , 2005, Experimental cell research.
[29] D. Birnbaum,et al. Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion. , 2005, International journal of oncology.
[30] Rong Zeng,et al. Regulation of PTEN by Rho small GTPases , 2005, Nature Cell Biology.
[31] R. V. van Etten,et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. , 2004, Cancer cell.
[32] J. Cowell,et al. The Oncogenic Fusion Protein-tyrosine Kinase ZNF198/Fibroblast Growth Factor Receptor-1 Has Signaling Function Comparable with Interleukin-6 Cytokine Receptors* , 2003, The Journal of Biological Chemistry.
[33] J. Melo,et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. , 2001, Blood.